Clinical Trial Update: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment [Phase 3]

View source ↗

Summary

This entry describes a Phase 3 trial evaluating talquetamab in combination with daratumumab (or with daratumumab and pomalidomide) versus daratumumab with pomal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Pomalidomide (Pomalidomide)
• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING